ClinicalTrials.gg
TerminatedNCT06046066Updated May 7, 2026

A Phase 1 Study of NM6603 in Advanced Solid Tumors

A Phase 1 interventional study of NM6603 in Cancers, sponsored by NucMito Pharmaceuticals Co. Ltd.. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by NucMito Pharmaceuticals Co. Ltd. · Phase 1, Interventional, and Treatment

Why this study was terminated
Discontinuation based on a strategic sponsor decision, not driven by safety concerns.

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is to assess the MTD and RP2D of NM6603 in adult patients with advanced solid tumors.

Read the detailed description

This is a Phase 1, first-in-human, multicenter, open label, 3+3 dose escalation study designed to evaluate the safety profile, the maximum tolerated dose (MTD), the recommended Phase 2 dose (RP2D), the pharmacokinetic and the preliminary antitumor activity of NM6603 in patients with advanced solid tumors. The study has two parts. In Part 1, NM6603 will be administered once daily. In Part 2, NM6603 will be administered twice daily to explore the effect of twice daily dosing on the pharmacokinetic, safety and tolerability, and anti-tumor activity profile of NM6603,

02

Conditions studied

  • Cancers

Browse trials for

Keywords

  • advanced solid tumors
03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's enrollment of 17 is below the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

NucMito Pharmaceuticals Co. Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Have a or cytologically confirmed diagnosis of advanced solid tumor;
  2. Have advanced or disease to standard curative or palliative therapy or to standard therapy;
  3. Have objective (assessable through clinical signs, symptoms, and/or laboratory findings) and radiologically-confirmed progression of disease at Screening;
  4. Patients must have based on v1.1;
  5. ≥ 18 years of age;
  6. Patients must exhibit a/an performance status of 0-2;
  7. Have a of at least 12 weeks (in the opinion of the investigator);
  8. Have adequate bone marrow reserve:

    1. ≥1.5×109 cell/L;
    2. count ≥100×109 cell/L;
    3. at least ≥9.0 g/dL
  9. Have adequate liver function:

    1. Total serum ≤ 1.5× (ULN);
    2. (ALT) and aspartate aminotransferase (AST) ≤2.5× ULN or ≤5.0× ULN in case of documented hepatic metastasis;
    3. Alkaline phosphatase ≤ 5× ULN
  10. Have adequate renal function:

    1. ≥60 mL/min (calculated according to the formula of Cockcroft and Gault);
    2. No abnormalities in the urinalysis results
  11. Are capable of swallowing study medication and following directions regarding taking study drug;
  12. Women of (WOCBP) and Women of non-childbearing potential are eligible to participate. Both women of childbearing potential and women of non-childbearing potential should use an approved method of and agrees to continue to use this method for the duration of the study and for 90 days after taking the last dose of study drug.

    Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only) (e.g., diaphragm, cervical cap, male condom, and female condom and spermicidal foam, sponges, and film), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile (e.g., bilateral tubal ligation, hysterectomy) for at least 3 months before screening or two years at time of screening. All male subjects/partners (excluding men who have been sterilized) must agree to consistently and correctly use a condom for the duration of the study and for 90 days after taking the study drug. In addition, subjects may not donate sperm for the duration of the study and for 90 days after taking study drug.

    Note: Women of non-childbearing potential who are less than two years postmenopausal should be tested for pregnancy. Any verbal confirmation of postmenopausal status will be recorded in source documents and appropriate page of CRF.

  13. WOCBP must have a negative serum pregnancy test at Screening Visit and negative urine pregnancy test prior to receiving the first dose of study drug; and
  14. Patients must have the ability to understand and the willingness to sign a written prior to registration on study.

Exclusion Criteria: Subjects meeting any of the following criteria will be excluded from enrollment:

  1. Have unresolved toxicity from previous treatment or previous agents, excluding alopecia. Clinical judgment by the investigator is allowed to determine if grade 1 fatigue at screening is residual toxicity from prior treatment or is a symptom of the patient's general condition or disease or if > Grade 1 toxicities are non-clinically relevant such as Lymphopenia. The investigator and medical monitor will discuss the eligibility of patients with baseline toxicity;
  2. Have signs or symptoms of end organ failure, major chronic illnesses other than cancer, or any severe concomitant conditions which, in the opinion of the investigator, make it undesirable for the patient to participate in the study, or which could jeopardize compliance with the protocol;
  3. Have evidence of another not in remission or history of such a malignancy within the last three years (except for treated basal or squamous cell carcinoma of the skin, or in situ cancer of the cervix);
  4. Have abnormalities in the 12-lead that in the opinion of the Investigator increase the risk of participating in the study (e.g., sinus rhythm with PR interval > 240 ms or second degree or higher AV block, confirmed by a repeat ECG);
  5. Have ECG evidence of complete left bundle branch block or ventricular pacing;
  6. Have a history of long syndrome or prolonged QT interval corrected based on Fridericia's method (QTcF) >450 ms at screening;
  7. Require treatment with drugs known to be associated with Torsade de Pointes;
  8. Have experienced any of the following within the 6-month period prior to screening that would interfere with the subject's participation in the opinion of the treating investigator: unstable angina, myocardial infarction or cerebrovascular accident, , cardiac failure with known less than 40%;
  9. Have other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that would make the patient inappropriate for enrollment in this study;
  10. Have any mental or medical condition that prevents the subject from giving informed consent or participating in the trial;
  11. Have received anti-tumor therapies such as chemotherapy, hormone therapy, radiation therapy, or immunotherapy within 4 weeks or 4 half-lives (whichever is shorter or as agreed between the site PI and Medical Monitor) prior to starting the study drug;
  12. Have received systemic (either oral or intravenous steroids, excluding inhalers or topicals) for a duration ≥ 4 weeks at the daily dose equivalent to ≥7.5 mg of oral prednisone within the 12 weeks prior to starting study drug;
  13. Are currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 28 days or four half-lives (whichever is shorter, or as agreed between the site PI and Medical Monitor) prior to first study drug administration;
  14. Have known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Note: Subjects with previously treated may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability;
  15. Require treatment with strong inhibitors, strong inducers, and/or sensitive substrates of CYP1A2 and/or , and/or sensitive substrates of CYP2B6 or major drug transporters; This medication can be stopped and the patient enrolled after 4 half- lives of that drug, as determined by the PI.
  16. Are unwilling to or unable to comply with the requirement of the protocol; and
  17. Are pregnant or breastfeeding or expecting to conceive or have children within the projected duration of the trial, starting with the pre-screening or screening visit through the duration of study participation.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    NM6603, administered orally every day in 28-day cycles

    Drug: NM6603

Interventions

  • DrugNM6603

    NM6603 is an orally available investigational small molecule indicated for the treatment of solid malignancies including, but not limited to breast, liver, pancreatic, colorectal, cervical, melanoma and lung cancers.

06

What researchers measure

Primary outcomes

  1. To determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of NM6603 in patients with advanced solid tumors

    Time frame: 28 days

Secondary outcomes

  1. Efficacy of NM6603 by Objective Response Rate (ORR) via iRECIST

    Time frame: From first dose of study drug to up to ~ 12 months in absence of progressive disease or unacceptable toxicity or withdrawal of consent

  2. Efficacy of NM6603 by disease control rate (DCR) via iRECIST

    Time frame: From first dose of study drug to up to ~ 12 months in absence of progressive disease or unacceptable toxicity or withdrawal of consent

  3. Pharmacokinetics (PK) of NM6603 by maximum observed plasma drug concentration (Cmax)

    Time frame: 28 days

  4. Pharmacokinetics (PK) of NM6603 by apparent terminal elimination half-life (t1/2)

    Time frame: 28 days

  5. Pharmacokinetics (PK) of NM6603 by time to maximum observed plasma drug concentration (Tmax)

    Time frame: 28 days

  6. Pharmacokinetics (PK) of NM6603 by area under the plasma drug concentration-time curve (AUC) from time 0 to the time of the last quantifiable concentration (Tlast) (AUC0-t)

    Time frame: 28 days

  7. Pharmacokinetics (PK) of NM6603 by AUC from time 0 to infinity (AUC0-∞)

    Time frame: 28 days

  8. Safety of NM6603 by Dose-Limiting Toxicities

    Time frame: 28 days

  9. Safety of NM6603 by incidence and severity of treatment-emergent adverse events (TEAEs)

    The intensity of the event will be graded using CTCAE v5.0 criteria.

    Time frame: From first dose of study drug to up to ~ 12 months in absence of progressive disease or unacceptable toxicity or withdrawal of consent

07

Study locations

4 sites
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Cleveland Clinic Taussig Cancer Center
    Cleveland, Ohio 44195, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 73203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Apr 2025, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2023
First posted
Sep 21, 2023
StartActual
Aug 31, 2023
Primary completionActual
Apr 25, 2025
CompletionActual
Apr 25, 2025
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06046066
Lead sponsor
NucMito Pharmaceuticals Co. Ltd.
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Aug 31, 2023
Primary completion
Apr 25, 2025
Completion
Apr 25, 2025
Last update
May 7, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion